Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review Amy S. Levin, MD, Iris M. Otani, MD, Timothy Lax, MD, Ephraim Hochberg, MD, Aleena Banerji, MD The Journal of Allergy and Clinical Immunology: In Practice Volume 5, Issue 1, Pages 107-113.e1 (January 2017) DOI: 10.1016/j.jaip.2016.06.022 Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Figure 1 Modified National Cancer Institute Common Terminology Criteria for Adverse Events Scale. From National Cancer Institute.13 The Journal of Allergy and Clinical Immunology: In Practice 2017 5, 107-113.e1DOI: (10.1016/j.jaip.2016.06.022) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Figure 2 Rituximab same-day rechallenge—Grading and outcome. *Rechallenge at our institution is 50% standard infusion rate. †Among these patients, 2 had grade 1B, 4 had grade 2, 1 had grade 4 reactions. The Journal of Allergy and Clinical Immunology: In Practice 2017 5, 107-113.e1DOI: (10.1016/j.jaip.2016.06.022) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Figure 3 Evaluation of patients referred to allergy. Desens, Desensitization. The Journal of Allergy and Clinical Immunology: In Practice 2017 5, 107-113.e1DOI: (10.1016/j.jaip.2016.06.022) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Figure E1 Massachusetts General Hospital Rituximab Desensitization Protocol. The Journal of Allergy and Clinical Immunology: In Practice 2017 5, 107-113.e1DOI: (10.1016/j.jaip.2016.06.022) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions